Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DST-102
- Development stage
- Preclinical
- Lead developer
- DelSiTech
- Modality
- Peptides, Hydrogel Systems → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
DST-102 is an ultra long-acting product candidate being developed by DelSiTech for the treatment of metabolic diseases, including type 2 diabetes and obesity. The candidate utilizes DelSiTech's proprietary Silica Matrix technology, a biodegradable drug delivery platform that enables the sustained release of active pharmaceutical ingredients—specifically a glucagon-like peptide 1 (GLP-1) receptor agonist—over several months from a single subcutaneous injection. This approach is designed to improve patient adherence and provide stable therapeutic drug levels, addressing the significant unmet needs in chronic metabolic disease management by reducing the frequency of administration compared to current daily or weekly therapies.
02
Targets
Beyond the preview
Go deeper on DST-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DST-102.